HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160

Journal of Immunology

Volumn 160, Issue 4, 1998, Pages 2000-2012

  VanCott, Thomas C ^a   Kaminski, Robert W ^a   Mascola, John R ^b   Kalyanaraman, Vaniambadi S ^c   Wassef, Nabila M ^b   Alving, Carl R ^b   Ulrich, J Terry ^d   Lowell, George H ^e   Birx, Deborah L ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e Intellivax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INHALATIONAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; SUBCUTANEOUS DRUG ADMINISTRATION; VAGINA MUCOSA; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BINDING SITES, ANTIBODY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; NASAL LAVAGE FLUID; NASAL MUCOSA; NEUTRALIZATION TESTS; VACCINATION; VAGINA;

EID: 0032519965     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Forrest, B. D. 1991. Women, HIV, and mucosal immunity. Lancet 337:835.
2. Mestecky, J., W. H. Kutteh, and S. Jackson. 1994. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res. Hum. Retroviruses 10:S11.
3. Mestecky, J., and S. Jackson. 1994. Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines. J. Clin. Immunol. 14:259.
4. Miller, C. J., J. R. McGhee, and M. B. Gardner. 1993. Mucosal immunity, HIV transmission, and AIDS. Lab. Invest. 68:129.
5. Alving, C. R., V. Koulchin, G. M. Glenn, and M. Rao. 1995. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145:5.
6. Matyas, G. R., and C. R. Alving. 1996. Protective prophylactic immunity against intranasal ricin challenge induced by liposomal ricin A subunit. Vaccine Res. 5:163.
7. White, W. I., D. R. Cassatt, J. Madsen, S. J. Burke, R. M. Woods, N. M. Wassef, C. R. Alving, and S. Koenig. 1995. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 13:1111.
8. Lowell, G. H., C. Colleton, D. Frost, R. W. Kaminski, M. Hughes, J. Hatch, C. Hooper, J. Estep, L. Pitt, M. Topper, R. E. Hunt, W. Baker, and W. B. Baze. 1996. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun. 64:4686.
9. Orr, N., G. Robin, D. Cohen, R. Arnon, and G. H. Lowell. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390.
10. Morris, W. M., M. C. Steinhoff, and P. K. Russell. 1994. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12:5.
11. Marx, P. A., R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamschikov, D. Chen, and J. H. Eldridge. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323.
12. Eldridge, J. H., R. M. Gilley, J. K. Staas, Z. Moldoneanu, J. A. Meulbroek, and T. R. Tice. 1989. Biodegradable microspheres: vaccine delivery system for oral administration. Curr. Top. Microbiol. Immunol. 146:59.
13. O'Hagan, D. T., J. P. McGee, J. Holmgren, A. M. Mowat, A. M. Donachie, K. H. Mills, W. Gaisford, D. Rahman, and S. J. Challacombe. 1993. Biodegradable microparticles for oral immunization. Vaccine 11:149.
14. Moldoveanu, Z., J. K. Staas, R. M. Gilley, R. Ray, R. W. Compans, J. H. Eldridge, T. R. Tice and J. Mestecky. 1989. Immune responses to influenza virus in orally and systemically immunized mice. Curr. Top. Microbiol. Immunol. 146:91.
15. Mowat, A. M., K. J. Maloy, and A. M. Donachie. 1993. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 80:527.
16. Maloy, K. J., A. M. Donachie, D. T. O'Hagan, and A. M. Mowat. 1994. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81:661.
17. Dickinson, B. L., and J. D. Clements. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In Mucosal Vaccines. H. Kiyono and P. L. Ogra, eds. Academic Press. New York, p.79.
18. Holmgren, J., N. Lycke, and C. Czerkinsky. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11: 1179.
19. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
20. Elson, C. O. 1989. Cholera toxin and its subunits as potential oral adjuvants. Immunol. Today 146:29.
21. Lehner, T., L. A. Bergmeier, C. Panagiotidi, L. Tao, R. Brookes, L. S. Klavinskis, P. Walker, J. Walker, R. G. Ward, L. Hussain, A. J. H. Gearing, and S. E. Adams. 1992. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 258:1365.
22. Kubota, M., C. J. Miller, K. Imaoka, S. Kawabata, K. Fujihashi, J. R. McGhee, and H. Kiyono. 1997. Oral immunization with simian immunodeficiency virus p55-gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J. Immunol. 158:5321.
23. Russell, M. W., Z. Moldoveanu, P. L. White, G. J. Sibert, J. Mestecky, and S. M. Michalek. 1996. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect. Immun. 64:1272.
24. Gallichan, W. S., D. C. Johnson, F. L. Graham, and D. L. Rosenthal. 1993. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168:622.
25. Gallichan, W. S., and K. L. Rosenthal. 1995. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 13:1589.
26. Gallichan, W. S., and K. L. Rosenthal. 1996. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology 224:487.
27. Lubeck, M. D., R. J. Natuk, M. Chengalvala, P. K. Chanda, K. K. Murthy, S. Murthy, S. Mizutani, S. G. Lee, M. S. Wade, B. M. Bhat, R. Bhat, S. K. Dheer, J. W. Eichberg, A. R. Davis, and P. H. Hung. 1994. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res. Hum. Retroviruses 10:1443.
28. Meitin, C. A., B. S. Bender, and P. A. Small, Jr. 1991. Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine 9:751.
29. Lagranderie, M., A. Murray, B. Gicquel, C. Leclerc, and M. Gheorghiu. 1993. Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 11:1283.
30. Langermann, S., S. Palaszynski, A. Sadziene, C. K. Stover, and S. Koenig. 1994. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372:552.
31. Berggren, R. E., A. Wunderlich, E. Ziegler, M. Schleicher, R. C. Duke, D. Looney, and F. C. Fang. 1995. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J. Acquired Immune Defic. Syndr. 10:489.
32. McDermott, M. R., C. H. Goldsmith, K. L. Rosenthal, and L. J. Brais. 1989. T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2. J. Infect. Dis. 159:460.
33. de Haan, A., J. F. Tomee, J. P. Huchshorn, and J. Wilschut. 1995. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 13:1320.
34. de Haan, A., H. J. Geerligs, J. P. Huchshorn, G. J. van Scharrenburg, A. M. Palache, and J. Wilschut. 1995. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13:155.
35. de Haan, A., K. B. Renegar, P. A. Small, Jr., and J. Wilschut. 1995. Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. Vaccine 13:613.
36. Abraham, E. 1992. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine 10:461.
37. Abraham, E., and S. Shah. 1992. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J. Immunol. 149:3719.
38. Orr, N., R. Arnon, G. Rubin, D. Cohen, H. Bercovier, and G. H. Lowell. 1994. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines. Infect. Immun. 62:5198.
39. Mallett, C. P., T. L. Hale, R. W. Kaminski, T. Larsen, N. Orr, D. Cohen, and G. H. Lowell. 1995. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun. 63:2382.
40. Lowell, G. H. 1997. Proteosomes for improved nasal, oral, or injectable vaccines. In New Generation Vaccines, Second Edition, M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cohen, eds. Marcel Kekker, Inc., New York, NY. p. 193.
41. Lowell, G. H., R. W. Kaminski, S. Grate, R. E. Hunt, C. Charney, S. Zimmer, and C. Colleton. 1996. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun. 64:1706.
42. Van De Verg, L. L., A. B. Hartman, A. K. Bhattacharjee, B. D. Tall, L. Yuan, K. Sasala, T. L. Hadfield, W. D. Zollinger, D. L. Hoover, and R. L. Warren. 1996. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Infect. Immun. 64:5263.
43. Lowell, G. H., R. W. Kaminski, T. C. VanCott, B. Slike, K. Kersey, E. Zawoznik, L. Loomis, G. Smith, R. Redfield, S. Amselem, and D. L. Birx. 1997. Nasal immunization with HIV gp160 formulated with proteosomes, emulsomes and/or cholera toxin B subunit to induce serum, intestinal, lung and vaginal antibodies. J. Infect. Dis. 175:292.
44. O'Hagan, D. T., D. Rafferty, J. A. McKeating, and L. Illum. 1992. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. J. Gen. Virol. 73:2141.
45. Staats, H. F., W. G. Nichols, and T. J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:462.
46. Bukawa, H., K. Sekigawa, K. Hamajima, J. Fukushima, Y. Yamada, H. Kiyono, and K. Okuda. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:681.
47. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031.
48. Muster, T., B. Ferko, A. Klima, M. Purtscher, A. Trkola, P. Schulz, A. Grassauer, O. G. Engelhardt, S. A. Garcia, P. Palese, and H. Katinger. 1995. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:6678.
49. Kalyanaraman, V. S., R. Pal, R. C. Gallo, and G. Sarngadharan. 1988. A unique human immunodeficiency virus culture secreting soluble gp160. AIDS Res. Hum. Retroviruses 4:319.
50. Kalyanaraman, V. S., V. Rodriguez, F. Veronese, R. Rahman, P. Lusso, A. L. DeVico, T. Copeland, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1990. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 6:371.
51. Getchell, J. P., J. L. Heath, D. R. Hicks, C. Sporborg, C. R. McGrath, and V. S. Kalyanaraman. 1986. Continuous production of a cytopathic human T-lymphotropic virus in a permissive neoplastic T-cell line. J. Clin. Microbiol. 23:737.
52. VanCott, T. C., S. C. D. Veit, V. Kalyanaraman, P. Earl, and D. L. Birx. 1995. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. J. Immunol. Meth. 183:103.
53. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373.
54. Ribi, E., J. L. Cantrell, K. Takayama, H. O. Ribi, K. R. Myers, and N. Qureshi. 1986. Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A. In Immunobiology and Immunopharmacology of Bacterial Endotoxins. A. Szentivanyi and H. Friedman, eds. Plenum Press, New York, p. 407.
55. Ulrich, J. T., and K. R. Myers. 1995. Monophosphoryl lipid A as an adjuvant. In Vaccine Design: The Subunit and Adjuvant Approach. M. F. Powell and M. J. Newman, eds. Plenum Press, New York, p. 495.
56. Lowell, G. H., W. R. Ballou, L. F. Smith, R. A. Wirtz, W. D. Zollinger, and W. T. Hockmeyer. 1988. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 240:800.
57. Amselem, A. S., A. Yogev, E. Zawoznik, and D. Friedman. 1994. Emulsomes, a novel drug delivery technology. In Proceedings of the International Symposium on the Control and Release of Bioactive Materials. No. 21.
58. Wassef, N. M., C. R. Alving, and R. L. Richards. 1994. Liposomes as carriers for vaccines. Immunomethods 4:217.
59. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J. P. Kraehenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:15.
60. VanCott, J. L., H. F. Staats, D. W. Pascual, M. Roberts, S. N. Chatfield, M. Yamamoto, M. Coste, P. B. Carter, H. Kiyono, and J. R. McGhee. 1996. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1504.
61. Artenstein, A. W., T. C. VanCott, K. V. Sitz, M. L. Robb, K. F. Wagner, S. C. D. Veit, A. B. Rogers, R. P. Garner, J. W. Byron, P. R. Burnett, and D. L. Birx. 1997. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J. Infect. Dis. 175:265.
62. Belec, L., B. C. Tevi, X. S. Lu, T. Prazuck, and J. Pillot. 1995. Local synthesis of IgG antibodies to HIV within the female and male genital tracts during asymptomatic and pre-AIDS stages of HIV infection. AIDS Res. Hum. Retroviruses 11:719.
63. VanCott, T. C., F. R. Bethke, V. Kalyanaraman, D. S. Burke, R. R. Redfield, and D. L. Birx. 1994. Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules. J. Acquired Immune Defic. Syndr. 7:1103.
64. VanCott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155: 4100.
65. VanCott, T. C., J. R. Mascola, R. W. Kaminski, V. Kalyanaraman, P. L. Hallberg, P. R. Burnett, J. T. Ulrich, D. J. Rechtman, and D. L. Birx. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary HIV-1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319.
66. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340.
67. Mascola, J. R., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke. 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169:48.
68. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863.
69. Childers, N. K., F. R. Denys, J. F. McGhee, and S. M. Michalek. 1990. Ultrastructural study of liposome uptake by M cells of rat Peyer's patches: an oral vaccine system for delivery of purified antigen. Regional Immunol. 3:8.
70. Wetzler, L. W., Y. Ho, and H. Reiser. 1996. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J. Exp. Med. 183:1151.
71. Belec, L., T. Dupre, T. Prazuck, B. C. Tevi, J. M. Kanga, O. Pathey, X. S. Lu, and J. Pillot. 1995. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J. Infect. Dis. 172:691.
72. Mascart-Lemone, F., M. Gerard, M. Libin, A. Crusiaux, P. Franchioly, A. Lambrechts, M. Goldman, and N. Clumeck. 1995. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J. Infect. Dis. 172:1253.
73. Israel, Z. R., and P. A. Marx. 1995. Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees. J. Med. Primatol. 24:53.
74. Miller, C. J., D. W. Kang, M. Marthas, Z. Moldoveanu, H. Kiyono, P. Marx, J. H. Eldridge, J. Mestecky, and J. R. McGhee. 1992. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin. Exp. Immunol. 88:520.
75. Miller, C. J., M. B. McChesney, and X. Lu. 1996. Mucosal immune responses to SIV infection. Sem. Virol. 7:139.
76. Kozlowski, P. A., D. Chen, J. H. Eldridge, and S. Jackson. 1994. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res. Hum. Retroviruses 10:813.
77. Burnett, P. R., V. T. C., V. R. Polonis, R. R. Redfield, and D. L. Birx. 1994. Serum IgA-mediated neutralization of HIV type 1. J. Immunol. 152:4642.
78. Kozlowski, P. A., K. P. Black, L. Shen, and S. Jackson. 1995. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons: masking by IgG. J. Immunol. 154:6163.
79. Tschachler, E., V. Groh, M. Popovic, D. L. Mann, K. Konrad, B. Safai, L. Eron, F. di Marzo Veronese, K. Wolff, and G. Stingl. 1987. Epidermal Langerhans cells: a target for HTLV-III/LAV infection. J. Invest. Dermatol. 88:233.
80. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215.
81. Miller, C. J., P. Vogel, N. J. Alexander, S. Sutjipto, A. G. Hendrickx, and P. A. Marx. 1992. Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am. J. Pathol. 141:655.
82. Bomsel, M. 1997. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3:42.
83. Amerongen, H. M., R. Weltzin, C. M. Farnet, P. Michetti, W. A. Haseltine, and M. R. Neutra. 1991. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J. Acquired Immune Defic. Syndr. 4:760.
84. Furuta, Y., K. Eriksson, B. Svennerholm, P. Fredman, P. Horal, S. Jeansson, A. Vahlne, J. Holmgren, and C. Czerkinsky. 1994. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 91:12559.
85. Burns, J. W., M. Siadat-Pajouh, A. A. Krishnaney, and H. B. Greenberg. 1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104.
86. Mazanec, M. B., J. G. Nedrud, C. S. Kaetzel, and M. E. Lamm. 1993. A three-tiered view of the role of IgA in mucosal defense. Immunol. Today 14:430.
87. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69:1339.